Health, Education & Government
›
Life Sciences & Pharma
›
Clinical Development & Trials
Site Management
Regulated development and commercialization journeys where clinical, quality, and market access align.
ICON
Syneos Health
Premier Research
Javara
Inside this journey
-
Pre-Discovery
Align the room on outcomes, decision process, and constraints before deeper discovery.
-
Stakeholder Alignment
Confirm decision roles, timelines, key success criteria, and risk tolerances across sponsor stakeholders.
Alignment Questions
Quick Introductions — Tell Us Who You Are and What’s At Stake
- Briefly describe your role, team, and the study you’re currently trying to staff with sites (indication, phase, and target enrollment).
- Which therapeutic area best describes this study?
- What trial phase is this, and how many active sites do you expect at peak?
- What is the single most important problem you want a site partner to solve for this program?
- How would you describe your current level of urgency to secure high-performing sites?
- Who else on your team should we be talking to as we design site solutions?
When Promises Collapse — Which Site Problems Have You Learned to Live With?
- Which recurring site failure do you suspect your organization accepts as 'normal' but actually costs you the most?
- How often do those failures materially delay study milestones (e.g., database lock, interim analyses)?
- Tell us about a specific study where site performance derailed timelines — what happened and what was the tangible impact?
- What short-term fixes have you tried (e.g., site retraining, extra monitors, incentives), and why didn’t they stick?
- When these problems surface, who on your team feels the pressure most — and how does it show up emotionally or politically?
- If nothing changed, how much additional time or cost do you estimate these recurring issues will add to this program?
Who Really Decides — Are Your Stakeholders Aligned or Pulling in Different Directions?
- Who in your organization actually signs off on site selection and commercial terms — and is that the same person running day-to-day operations?
- Which stakeholder groups tend to have conflicting priorities when selecting sites (e.g., speed vs. quality vs. cost)?
- How do your stakeholders define acceptable risk when it comes to site-level uncertainty (e.g., enrollment variance, coordinator churn)?
- Give an example of a recent decision where stakeholder misalignment created a delay or suboptimal site choice.
- What evidence or assurances would each key stakeholder need to feel comfortable moving forward with a new site partner?
- Who must be pulled into final commercial negotiations to avoid late pushback?
How Truthful Is Your Feasibility — Are Your Numbers Based on Hope or on Hard Performance?
- Are your current feasibility projections driven primarily by historical site performance, investigator estimates, or population-level assumptions?
- Which data sources do you currently use to vet sites? Select all that apply.
- How often is historical enrollment performance for specific PIs or coordinators available and trusted in your feasibility decisions?
- Where do you see the biggest blind spots in your feasibility process (e.g., coordinator capacity, competing trials, local referral patterns)?
- If we could provide validated, site-level enrollment trajectories and coordinator retention history, how would that change your approach?
- What data format or dashboard view would make you feel confident enough to commit to a site (e.g., per-site forecast with confidence intervals, historical monthly enrollments)?
If Targets Were Hit but Patients Fell Through the Cracks — What Truly Defines Success?
- If enrollment met target but data quality or retention lagged, would you still call the program successful?
- Which of these metrics must be met for you to consider a site successful? (choose all that apply)
- What variance from forecast is acceptable at the site and study level (e.g., ±10%, ±20%) before you trigger corrective action?
- Describe the qualitative signals that worry you most about a site’s future performance (e.g., PI tone in calls, slow paperwork, frequent staff gaps).
- Which milestones or checkpoints would you want built into a partnership to signal early when a site is off-track?
- How would you prefer corrective actions be triggered and executed — centralized rapid-response team, local site remediation, or contractually defined remedies?
What Would It Take to Hand Over Trust — The Exact Moment You’d Switch Partners
- What are the non-negotiable proofs a new site partner must provide before you’ll move work off an incumbent?
- Which contract terms are deal-breakers for you (e.g., accountability for enrollment pacing, coordinator retention clauses, audit access)?
- Would you be open to a short pilot (e.g., 3–5 sites) to validate performance before broader rollout?
- What commercial structures do you prefer to align incentives to enrollment and retention?
- What evidence from a site audit or inspection would increase your confidence the fastest (select up to two)?
- How comfortable are you sharing de-identified historical feasibility outcomes to enable better forecasting from a partner?
Readiness & Next Steps — If We Partner, What’s the Fastest Realistic Path to First Patient In?
- If we agreed to proceed next week, what is the earliest realistic date for first patient in given your internal processes?
- Which of these site-level items are already available and accurate for this program? (select all that apply)
- What regulatory or legal hurdles typically slow your site activations in target countries?
- How would you like communication to be structured during start-up and early recruitment (e.g., weekly dashboard + monthly governance call)?
- What would make you feel confident enough to move from exploratory conversations to a short, structured qualification (pilot/POC)?
- Who will be the decision owner for moving to an initial qualification — name and role?
- Are there any non-negotiable compliance or audit requirements we should be aware of before proposing scope or SLAs?
-
Current State Mapping
Document existing site selection processes, recent failures (e.g., missed enrollment, coordinator turnover), and data sources used for feasibility.
Current State
Getting Oriented — a quick 2-minute snapshot
- Briefly describe the study you’re considering (phase, therapeutic area, unique protocol demands).
- What is your target total enrollment and the ideal first-patient-in timeline?
- Who on your team will own site selection and who signs final approval?
- How important is enrollment predictability versus speed for this program?
- Which outcomes would make this program feel successful at month 3 and at final readout?
What Keeps You Up at Night?
- Tell us about the single worst site-selection surprise you've experienced—and why it still matters to you.
- How often do surprises (missed enrollment, long regulatory delays, coordinator loss) occur across your studies?
- When those surprises happen, what are the top three downstream impacts you face (cost, timeline, data quality, sponsor trust, other)?
- How do these failures feel for the team—frustration, embarrassment, burnout, or something else? Give a short example.
- What would you say is your current tolerance for risk around under-performing sites?
How You Actually Pick Sites Today (versus how you wish you did)
- If an external auditor reviewed your last three site-selection decisions, would they call your approach data-driven or hope-driven—and why?
- Walk through the typical steps your team runs during feasibility and site selection—from outreach to final signoff.
- Which of these data sources do you rely on when scoring sites? (select all that apply)
- How do you weight past enrollment, regulatory speed, coordinator stability, and patient access when scoring a site? (briefly describe your scoring priorities)
- How long does your average feasibility round take from kickoff to commit, and what are the usual bottlenecks?
- Who must be consulted or give approval during selection (roles and levels)?
When Forecasts Fall Apart — a forensic conversation
- Think of a recent study where forecasted enrollment collapsed—what early signs were missed that, in hindsight, were obvious?
- Which root causes most often explain enrollment misses at your sites?
- How quickly do you detect divergence from forecast, and what metrics trigger escalation?
- Describe a corrective action that worked and one that didn’t—what separated them?
- When a site under-performs, who typically leads remediation and what authority do they have?
- How much of underperformance do you attribute to structural problems (process, staffing) versus one-off people issues?
Data You Trust — and the Quiet Gaps You Don’t Talk About
- Which single data element do you consider the most reliable predictor of a site’s future enrollment?
- Rate the reliability of these sources in your feasibility work: internal site records, EHR extracts, PI self-reports, CRO feasibility assessments.
- What data do you wish you had but don’t—be specific about fields, refresh cadence, or visibility gaps.
- How standardized are the metrics you use across programs (definitions for active coordinator, open-to-screen patients, screen-to-enroll)?
- Do you use predictive models or enrollment forecasting tools today? If yes, which inputs are most trusted and which are ignored?
- How often do you validate feasibility assumptions against real-world site performance post-selection?
People, Power, and Who Actually Makes It Happen
- If your highest-performing site left the network tomorrow, how long before you’d see the impact—and how would you respond?
- What’s your current model for site staffing and ownership—are coordinators centralized, employed by sites, or contracted via SOWs?
- How do you measure and incentivize coordinator retention and performance today?
- Describe backup coverage plans for coordinator turnover or PI unavailability—are they documented and practiced?
- Who on your team champions site quality metrics post-activation (enrollment pacing, data queries, retention), and how often are they reviewed?
- What would make a long-term partnership with a dedicated site network genuinely appealing to you?
If Everything Worked — a short exercise in outcome clarity
- Imagine this study hit 100% of forecast on schedule—what concrete changes would that create for your program and your career?
- Which three metrics would you use to prove the partnership succeeded (pick up to three)?
- What level of deviation from forecast is acceptable before you require a formal remediation plan?
- How much transparency into site-level operations and staffing would you want in a partnership (dashboards, raw data access, scheduled reviews)?
- What non-negotiable guarantees or SLAs would push you to pilot a new site model?
Small Tests, Big Signals — are you ready to try something different?
- What’s the smallest pilot you would run to test a new site-selection approach that promises better predictability?
- What constraints would prevent you from running that pilot in the next 60 days?
- Which stakeholders must be engaged to approve a pilot, and how do they prefer to receive results (presentation, dashboard, raw data)?
- What artifacts would we need from you to scope a meaningful pilot (past feasibility reports, site performance logs, EHR cohort queries)?
- How would you define success for a 3-month pilot—what signals would make you continue or stop?
- Are you open to a brief data-sharing agreement so we can validate feasibility against your historical site outcomes?
Deciding the Next Move — practical commitments and timing
- If we could demonstrate a model that reduces your enrollment variance by half, what timeline would you need to make a decision?
- Who else needs to be in the room for a pilot planning conversation (names/roles)?
- Do you have any legal, procurement, or compliance constraints we should know about before proposing a pilot?
- What is the single most important piece of evidence you’d need from us to feel confident moving forward?
- Would you like to schedule a 30-minute working session to co-design a feasibility-to-pilot plan?
-
-
Outcome Discovery
Define target enrollment, timelines, acceptable variance, quality expectations, and what success looks like at study milestones.
Discovery Questions
Start with the North Star: What outcome truly matters?
- In one sentence, what single enrollment outcome would make this study feel successful to you?
- What is the numeric target for randomized/enrolled patients at the program level and the expected per-site average?
- What are your target dates for First Patient In (FPI) and Last Patient In (LPI)?
- How much variance from the enrollment target is acceptable before you would consider corrective action?
- Which quality signals matter most when you evaluate whether enrollment is valuable (select all that apply)?
- Who are the stakeholders that will ultimately judge success and how does each define it?
Imagine We Miss the Target — Tell Me the Real Cost
- If enrollment came in 30% below target, who in your organization feels it first and what breaks down next?
- Which business impacts are most concerning if enrollment lags (select all that apply)?
- Which operational milestones or downstream decisions would you need to pause or revisit if enrollment is slower than forecast?
- From past experience, which sponsor actions produced the fastest recovery when enrollment underperformed?
- How does the possibility of sustained under-enrollment make you feel about vendor relationships and your ability to meet program goals?
What Would 'On-Time, On-Target' Actually Feel Like?
- Beyond hitting numbers, how would working with a partner who reliably delivers enrollment change your daily responsibilities and stress?
- What reporting cadence and level of detail would make you feel informed and comfortable (pick one)?
- Which internal stakeholders must be included in enrollment communications and in what format (select all that apply)?
- What specific escalation thresholds (e.g., % below forecast, weeks behind) would trigger immediate corrective actions in your view?
- If delivery is steady, what tangible trust signals would you present internally to sustain funding and executive support?
Where Have Forecasts Been Wrong Before?
- When forecasts failed on earlier programs, what single hidden assumption do you most wish had been challenged up front?
- Which root causes recur most often when site-level forecasts diverge from reality (select all that apply)?
- Tell me about a specific study where feasibility projections didn’t match delivery—what were the earliest warning signs you now recognize?
- How long did it typically take from the first warning sign to meaningful corrective action, and what created that delay?
- Which mitigation strategies you tried actually produced measurable improvements, and which felt like wasted effort?
How Much Trust Do You Have in the Numbers?
- If you had to grade the credibility of your current feasibility and forecast data, what grade would you give and why?
- Which data sources carry the most weight for your forecasts (select all that apply)?
- When you build a forecast, how do you typically balance historical performance vs. site-reported enthusiasm?
- How often should forecasts be refreshed during startup and recruitment so you feel confident in decisions?
- What level of transparency into the assumptions (e.g., referral funnel, screen-fail rate, pre-screen sources) do you require for each site's forecast?
What Quality Looks Like — Not Just Numbers
- Would you accept enrollment that meets targets but produces data you cannot rely on?
- What is your acceptable maximum rate of major protocol deviations at site level?
- What is an acceptable average query rate per Case Report Form (CRF) that still allows confident analysis?
- What maximum lost-to-follow-up rate through the primary endpoint would you accept?
- Which monitoring approach gives you the confidence required for data you can act on?
- What contractual quality KPIs or SLAs (e.g., query resolution time, deviation rates) would make you comfortable committing?
Decision Triggers and Timeline — When Do We Pull the Lever?
- What single metric or event would prompt you to change the study plan or vendor mid-program?
- Which checkpoint do you require before escalating corrective measures (choose one)?
- Who has final authority to approve major scope changes such as opening new sites or reallocating budget?
- What commercial protections or incentives do you require up front (select all that apply)?
- What decision-making evidence and cadence will you need to authorize scaling or contract renewal?
A Small First Win — What's the Easiest Way to Start Together?
- If we had to prove value in 30 days, what three measurable things would convince you our network can deliver?
- Would you be open to a limited pilot to validate projections and processes?
- What would acceptable success criteria be for a pilot (select all that apply)?
- How would you prefer pilot onboarding and training to be structured?
- Who must sign off to scale from pilot to full program and what specific evidence will they request?
-
Solution Experience
Validate how our network delivers the customer’s outcomes using their protocol, historical site performance, and enrollment forecasting scenarios.
Experience Meetings
- Experience Pre-Work & Alignment
- Protocol-to-Site Capability Mapping (Operational Diagnosis)
- Historical Performance Review & Enrollment Forecasting (Proof)
- Enrollment Risk Simulation & Mitigation Playbook (Problem -> Proof of Controls)
- Solution Validation & Decision Checkpoint (Force Validation & Commit Signals)
- Assign owners for each mitigation action and agree monitoring cadence.
- Deliver validated, site-level enrollment forecasts tied to sponsor protocol and historical performance.
- Ensure sponsor accepts at least one realistic scenario as the operational baseline (base case) or requests defined adjustments.
- Expose which sites reliably meet targets and which require mitigation or replacement.
- Seller to deliver a per-site forecast report (scenarios, assumptions, timelines) within 48 hours.
- Sponsor to flag any forecast assumptions they reject and provide alternate inputs if needed.
- Recommend site shortlist (include back-up sites) based on forecasted contribution to enrollment targets.
- Top Risks & Impact Quantification
- Prove that, under plausible adverse scenarios, the seller's network and playbook can return enrollment to target within agreed tolerances.
- Agree operational SLAs and trigger thresholds that will be used to govern active mitigation.
- Introductions & Objectives
- Seller to produce a Mitigation Playbook (actions, owners, timelines, expected impact) and share within 72 hours.
- Sponsor to approve SLA trigger thresholds or propose modifications.
- Establish monitoring cadence (weekly enrollment sync, monthly review) and invite list.
- Restate Current State, Consequence, Future State
- Obtain explicit sponsor validation that the proposed site network and forecast meet the agreed Future State or capture a short, prioritized list of remaining objections.
- Secure agreement on measurable acceptance criteria and SLAs to be included in the commercial and operational terms.
- Agree clear next steps and owners to move from Solution Experience to Solution Scope/Mutual Commit stages.
- Sponsor to sign or complete a validation checklist confirming acceptance criteria or to submit prioritized objections within 5 business days.
- Seller to deliver a Solution Experience executive summary (current state, quantified consequence, validated forecast, mitigation playbook, proposed SLAs) for contract handoff.
- Schedule the Solution Scope / Commercial handoff meeting with required stakeholders.
- Sponsor and seller agree a clear, one-sentence Current State describing the problem scope.
- Sponsor quantifies the consequence of the current state in operational or financial terms.
- Agree a one-sentence Future State and measurable success criteria to prove during the experience.
- Confirm delivery of protocol and historical site performance data necessary for scenario modeling.
- Sponsor to upload final protocol, cohort targets, and historical site datasets (deadline: 3 business days).
- Seller to prepare a concise summary: current-state sentence, quantified consequence table, and proposed future-state sentence for validation.
- Schedule hands-on forecasting and mapping sessions and circulate detailed agendas.
- Protocol Highlights & Constraints
- Produce a site-by-protocol gap list that links operational constraints to enrollment and start-up risk.
- Agree which site-level adaptations or resourcing changes would be required to achieve the Future State.
- Identify representative sites (by performance tier) to include in the forecasting exercise.
- Seller to produce a site-capability matrix mapping protocol tasks to staffing and time estimates.
- Sponsor to confirm acceptable protocol adaptations or critical non-negotiables.
- Select 6–8 representative sites (high/medium/low performers) for the forecasting session.
- Overview of Historical Site Metrics
- Live Simulations of Divergence Scenarios
- Forecasting Methodology & Assumptions
- Summarize Forecasts & Proof Points
- Patient Journey & Screening Pathways
- One-Sentence Current State
- Run Scenario Forecasts Live
- Quantify the Consequence
- Review Acceptance Criteria & SLAs
- Site Capability Mapping
- Mitigation Playbook Review
- Stakeholder Validation
- Map Forecasts to Consequences
- Agree SLA Triggers & Escalation Path
- Identify Key Mismatches & Bottlenecks
- Define Future State & Success Criteria
- Next Steps & Handoff
- Validation Checkpoint
- Force Validation
- Pre-Work & Data Confirmation
- Logistics & Next Steps
-
Solution Scope
Define included sites, staff roles, deliverables (feasibility, regulatory start-up, recruitment, data ops), and measurable acceptance criteria.
Scope Configuration
- Provide Dedicated Principal Investigators
- Deploy Dedicated Clinical Research Coordinators
- Prepare and Submit IRB/EC Applications
- Conduct Site Initiation Visit and Staff Training
- Execute Patient Recruitment Campaigns
- Perform On-site Patient Screening and Informed Consent
- Collect and Enter Source Data into EDC
- Manage Investigational Product Accountability and Dispensing
- Process, Store, and Ship Clinical Samples
- Identify and Report Serious Adverse Events
- Resolve Data Queries and Clean CRFs
- Support Sponsor Monitoring Visits with Documentation
- Perform Protocol Procedures (ECG, PK draws, imaging)
Scope Questions
Provide Dedicated Principal Investigators
- Will the sponsor require a site-dedicated PI (sole PI for the trial) or is a shared PI across studies acceptable?
- What therapeutic area experience or certifications are mandatory for the PI (e.g., oncology, cardiology, prior device trials)?
- How many active studies per PI is acceptable during this trial period?
- What minimum PI percent effort or weekly hours should be committed to oversight and source review?
- Are PI backup/alternate investigators required for coverage during vacations or conflicts?
- What acceptance criteria will you use for PI performance (e.g., enrollment targets, query response time, timely SAE review)?
Deploy Dedicated Clinical Research Coordinators
- Do you require a dedicated CRC per site or a shared CRC model across multiple sites?
- What minimum coordinator experience level is needed (years of experience / prior phase experience)?
- What coordinator FTE allocation is expected at study launch and during peak enrollment?
- Should coordinators be credentialed in specific procedures (ICF, ECG, blood draws, device handling)? Please list.
- Are coordinator turnover SLAs or retention guarantees required (e.g., max replacement frequency or ramp time)?
- What coordinator performance metrics will be used to accept site staffing (e.g., enrollment per month, query closure time)?
Prepare and Submit IRB/EC Applications
- Will the sponsor use a central IRB/EC, local IRB/EC, or allow either?
- Are site templates or sponsor templates required for submission, and who will provide them?
- What is the target IRB/EC approval timeline (weeks) for first site activation?
- Do submissions require translated documents for non-English sites or multi-country ECs?
- Who is responsible for preparing consenting documents, Annexes, and regulatory binders (Sponsor, CRO, Site)?
- List any special regulatory requirements (e.g., pediatric consent, vulnerable populations, device investigational device exemptions).
Conduct Site Initiation Visit and Staff Training
- Should SIVs be conducted onsite, remotely, or hybrid?
- What core training topics are mandatory for staff (e.g., protocol, ICF, safety reporting, EDC, GCP)?
- Are sponsor-led SIV content and checklists provided or shall the site use standardized checklists?
- What documentation must be present to pass SIV (e.g., signed delegation log, CVs, training records)?
- Do you require competency assessments or post-training evaluations for coordinators and PI?
- What timeline between SIV completion and first patient in (FPI) is acceptable?
Execute Patient Recruitment Campaigns
- What recruitment channels should be included (e.g., EMR prescreening, community outreach, paid digital ads)?
- What monthly enrollment targets per site are expected at launch and steady state?
- Do campaigns require sponsor approval of messaging and materials prior to deployment?
- Will recruitment include targeted HIPAA-compliant patient outreach from EMR lists?
- Are paid media budgets managed by sponsor or by site/CRO and is tracking required (source attribution)?
- What KPIs define acceptable recruitment performance (e.g., screening-to-randomization ratio, cost per enrolled patient)?
Perform On-site Patient Screening and Informed Consent
- Will consent be taken in-person only or is eConsent/remote consent permitted?
- What prescreening documentation and labs must be completed prior to consent or at screening visit?
- Do you require a witness for consent or specific language for vulnerable populations?
- What maximum acceptable screen-fail rate and expected screen-to-enroll ratio should be used to plan resources?
- Who maintains ICF versions and reconsent records (site binder, EDC, eConsent platform)?
- Are dedicated private spaces or translator services required for consent visits?
Collect and Enter Source Data into EDC
- Which EDC platform will be used and will sites need pre-configured accounts or training?
- What acceptable lag time from source event to EDC entry is required (e.g., same day, 48 hours)?
- Do you require source document templates and what source file types are acceptable (electronic, scanned PDF, proprietary EMR extracts)?
- Are remote source access arrangements needed for SDV or will monitors come onsite?
- What data quality KPIs will determine acceptance (e.g., query rate per CRF page, discrepancy rate)?
- Who is responsible for EDC query resolution and what SLA is expected for first response?
Manage Investigational Product Accountability and Dispensing
- Will investigational product (IP) be shipped to sites directly or to a depots/distribution hub?
- What storage requirements exist at site (temperature ranges, monitored storage, backup power)?
- What dispensing model is required (blinded kits, unblinded pharmacy, randomization at site)?
- What documentation and logs are required for IP accountability and returns?
- Are onsite pharmacy staff or trained coordinators responsible for dispensing and reconciling IP?
- What acceptable timelines are there for reporting dispensing errors or temperature excursions?
Process, Store, and Ship Clinical Samples
- What sample types and processing are required (blood for PK, serum, plasma, swabs, biopsies)?
- Are pre-analytical processing SOPs needed at site (centrifugation, aliquoting, freeze times)?
- What storage conditions and hold times are required prior to shipment (freezer temp, monitored storage)?
- Who performs shipping logistics and which couriers/lab partners are mandated by sponsor?
- Are chain-of-custody logs, temperature logs, and shipment tracking required for each sample batch?
- Are sample labeling and kit preparation handled by site or centralized lab, and are barcode systems required?
Identify and Report Serious Adverse Events
- What SAE reporting timelines are required (e.g., 24-hour initial report, 7-day follow-up)?
- Will the site use an electronic safety portal or Sponsor/CRO AE case reporting form?
- Who is responsible for initial causality and expectedness assessments (site PI, sponsor, safety team)?
- Are medical monitor contact procedures and on-call escalation paths required to be documented at site?
- Do you require SAE training refreshers and competency checks for staff before activation?
- What acceptance criteria determine adequate safety reporting (e.g., timeliness, completeness, follow-up documentation)?
-
Mutual Commit
Finalize commercial terms, SLAs (enrollment pacing, coordinator retention), audit expectations, and mutual responsibilities.
Agreement Modules
- Master Services Agreement (MSA)
- Statement of Work (SOW)
- Service Level Agreement (SLA)
- Pricing & Payment Schedule
- Performance Guarantee & Remediation Plan
- Audit, Inspection & Monitoring Agreement
- Data Processing Agreement (DPA)
- Regulatory Roles & Responsibilities Matrix
- Principal Investigator & Staff Assignment Commitment
- Change Order & Scope Management
- Termination & Transition Plan
- Insurance & Indemnification Schedule
- Acceptance Criteria & Closeout Sign-off
- Confidentiality & IP Rights Addendum
-
Deployment
Operationalize rollout with regulatory startup, staffing, recruitment launch, and validation.
-
Pre-Deployment Readiness
Verify site-level documents, PI availability, coordinator assignments, and regulatory milestones are on-track for activation.
Readiness Questions
Start Here — What's Most Top-of-Mind?
- In one sentence, what’s the single biggest site-selection or enrollment worry that brought you to this conversation?
- Which upcoming study (or milestone) is this about?
- Who on your team will feel the impact most if this issue continues?
- How quickly do you need to see measurable improvement in enrollment or site readiness?
- Briefly, how have prior vendors or sites fallen short on similar programs?
When Promises Fall Flat — Are Feasibility Numbers Actually Worth Anything?
- Are you still treating feasibility projections as actionable plans—or have you learned to discount them entirely?
- Over the last three studies, what percentage of projected enrollment did selected sites actually deliver on average?
- Which patterns explain underperformance most often at your sites? (pick all that apply)
- Tell a short story about one site that looked great on paper but failed in practice—what happened and when did you first see the warning signs?
- How long do you typically tolerate underperforming sites before adjusting or replacing them?
What Does the Real Damage Look Like?
- If under-enrollment continues on your next study, which outcome worries you most — time, budget, data integrity, or reputation?
- Quantitatively, how many months of delay or what percent budget overrun becomes a crisis for your program?
- Describe the stakeholder pressure you face when enrollment misses occur—who asks for explanations and how are decisions made?
- Have missed forecasts ever jeopardized a regulatory filing or a partnership? If so, summarize what happened.
- Emotionally, how does recurring underperformance affect your team’s willingness to try new vendors or site models?
What You’ve Tried — Which Fixes Actually Stuck?
- Which interventions have you tested to improve site delivery that felt promising but then failed?
- When an intervention failed, what was the primary reason it didn’t scale or sustain?
- Have you had a past vendor or partner successfully turn around a chronically underperforming site? What did they change first?
- What tactical levers do you still believe could improve outcomes if executed reliably?
- What internal barriers typically block adoption of promising fixes (budget, procurement, legacy CRO contracts, etc.)?
Imagine First Patient In — What Would Make You Breathe Easier?
- What single piece of evidence would make you confident a site will hit first-patient-in on schedule?
- What are your minimum acceptable ranges for enrollment vs forecast and coordinator retention?
- Which site readiness items must be completed before you consider activation a 'go'?
- How do you prefer activation evidence to be reported and validated (frequency and format)?
- If a site met all your activation criteria but missed first patient in by X days, what corrective action would you expect immediately?
Hidden Constraints — What Can Derail Activation at the Last Minute?
- Which oft-overlooked operational issue has derailed activation in the past and surprised you most?
- How long does your typical regulatory startup take from contract signature to site activation today?
- Which regulatory or contractual milestone routinely slips and why?
- What role do local PI schedules (clinical load, vacations, moonlighting) play in delays—how do you currently account for that risk?
- How much buffer time do you want built into activation plans to absorb unexpected issues?
Decision Rights & Acceptance — Who Really Signs Off?
- Will there be any internal stakeholders who can veto site acceptance after operational readiness is demonstrated?
- Who needs to approve commercial terms, and what is your fastest internal approval timeline?
- What acceptance criteria would you include in an SLA for site activation and early enrollment?
- If we proposed a pilot of 3–5 sites to prove capability, what governance or exit criteria would you require?
- How will you judge whether a site management partner is a long-term fit beyond a single study?
What Would Make You Say 'Go' — Your Smallest Risky Bet
- If we handed you one site packet today that met your top readiness checks, what evidence would you need to green-light it for activation?
- Would you be open to a short, measurable pilot (e.g., 30–60 day guarantee) to validate performance? If so, what timeframe feels reasonable?
- What KPIs must be achieved in a pilot for you to consider broader rollout?
- What reporting cadence and transparency would make you comfortable (dashboard, audit trail, on-call escalation)?
- What would a successful first 90 days look like to you—describe the top three outcomes you'd expect?
-
Site Onboarding & Regulatory Start-up
Execute contracts, train staff on protocol/SOPs, and complete regulatory submissions to enable first patient in timelines.
-
Recruitment Launch & Monitoring
Initiate recruitment, track enrollment vs forecast, apply retention tactics, and run rapid corrective actions when forecasts diverge.
-
-
Success Review
Review enrollment delivery, retention, and data quality against agreed success signals and capture continuous improvements or issues.
Success Reviews
- Executive Success Review
- Enrollment & Retention Performance Deep Dive
- Data Quality & Monitoring Review
- Continuous Improvement & Lessons Learned Workshop
Issues & Enhancements
- Revise monitoring checklist to include newly identified systemic checks and deploy to monitors within 5 business days.
- Diagnose why enrollment or retention deviates from forecast at the site level with evidence-backed causes.
- Define prioritized, time-bound corrective actions for each affected site with clear owners.
- Establish measurable short-term checkpoints to validate recovery or trigger further escalation.
- Site leads to submit revised recruitment action plans (including outreach channels and weekly targets) within 72 hours.
- Central recruitment team to launch targeted campaigns for top 3 high-impact regions within 7 days and report weekly metrics.
- Schedule 30-day checkpoint calls for all corrected sites and prepare pre-read performance packs 48 hours prior.
- Summary of Data KPIs
- Confirm whether current data quality meets acceptance criteria required for regulatory readiness and interim analyses.
- Create a prioritized remediation plan with measurable verification steps for each major data issue.
- Set clear escalation triggers to protect data integrity and study timelines.
- Data operations to run a data-cleanup sprint for high-priority query types and deliver a remediation status report in 10 business days.
- Schedule focused training sessions for sites with repeat errors and issue attendance & completion reports.
- Welcome & Objectives
- Retrospective Framing & Pre-work Review
- Capture a prioritized list of durable improvements and designate owners to update SOPs/playbooks.
- Ensure learnings are operationalized (training, process change, templates) so they inform future site activations and studies.
- Agree on measurements and a cadence to verify that implemented changes produce expected improvement.
- Document the top 5 improvements, assign owners, and publish an updated study playbook within 14 days.
- Develop a short training module for any new processes and schedule mandatory completion for all site CRCs and monitors within 30 days.
- Define 60- and 120-day metrics to track the impact of changes and schedule follow-up reviews.
- Ensure sponsor and SMO leadership have a shared, quantified view of whether study success signals are met.
- Obtain executive decisions on escalation, reallocation, or closure options based on evidence presented.
- Assign clear owners and deadlines for agreed next steps or corrective decisions.
- Circulate the executive KPI pack (enrollment, retention, data quality) with decision rationale within 48 hours.
- Sponsor to confirm chosen executive action (e.g., approve additional recruitment budget or site replacement) within 5 business days.
- If escalation approved, schedule a targeted deep-dive within 3 business days with identified owners.
- Pre-work Review
- Site-Level Data Exceptions
- What Worked Well
- Site Performance Heatmap
- One-line Current State Summary
- Monitoring Findings & Action Status
- Key Metrics Snapshot
- What Could Be Improved
- Root-Cause Walkthrough (per site)
- Translate to Process Changes
- Root Causes & Systemic Gaps
- Major Risks & Consequences
- Retention & Visit Adherence Analysis
- Create Playbook & Training Backfill
- Corrective Action Options & Prioritization
- Recommended Decisions
- Remediation Plan & Verification
- Assign Owners & Timelines
- Escalation Criteria
- Close-out & Measurement
- Agreement & Next Steps